Table 1

Demographics and baseline characteristics

Placebo (n = 232)Ranolazine (n = 232)
Age, years (mean ± SD)56 ± 9.355 ± 9.5
Female48.7%53.0%
White race90.1%91.8%
Ethnicity
 Hispanic or Latino13.4%12.5%
 Not Hispanic or Latino86.6%87.1%
 Not reported00.4%
Weight, kg (mean ± SD)92.1 ± 17.593.2 ± 16.4
BMI, kg/m2 (mean ± SD)32.8 ± 4.8532.8 ± 4.75
eGFR, mL/min/1.73 m2 (mean ± SD)83.3 ± 18.484.5 ± 18.8
HbA1c, % (mean ± SD)8.01 ± 0.7278.06 ± 0.732
HbA1c, mmol/mol (mean)6465
FSG, mg/dL (mean ± SD)171.5 ± 34.45172.1 ± 34.32
Diabetes duration, years (mean ± SD)3.0 ± 4.003.0 ± 4.29
Took prior antihyperglycemic agent (any)22.0%19.8%
 Sulfonylureas4.7%4.7%
 Biguanides17.2%15.9%
Concomitant lipid-lowering therapy (any)21.1%21.1%
 Statins17.7%18.1%
 Fibrates3.0%2.2%
 Niacin00
 Other3.0%2.2%
  • eGFR, estimated glomerular filtration rate.